Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7322
    -0.0001 (-0.01%)
     

  • CRUDE OIL

    83.82
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    87,916.43
    +14.47 (+0.02%)
     

  • CMC Crypto 200

    1,391.68
    +9.11 (+0.66%)
     

  • GOLD FUTURES

    2,345.20
    +2.70 (+0.12%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,774.50
    +207.00 (+1.18%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,780.35
    +151.87 (+0.40%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Stocks in play: Lattice Biologics Ltd.

Baystreet.ca

Announced financial results for Q2 2019. Gross profit margin was 77.0% for the three months ended March 31, 2019, compared to 68.2% for the same period in the previous year. For the three months ended March 31, 2018, sales increased over 100% year over year, while gross profit also increased over 100% year over year. The company recognized net income of $0.1 million ($0.00 per share) for the three months ended March 31, 2019 compared to a net loss of $0.2 million ($0.00 per share) for the same period in the previous year. Lattice Biologics Ltd. shares V.LBL are trading unchanged at $0.04.